Compare CVLG & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVLG | GOSS |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.4M | 726.8M |
| IPO Year | 1994 | 2019 |
| Metric | CVLG | GOSS |
|---|---|---|
| Price | $21.72 | $3.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $36.00 | $8.60 |
| AVG Volume (30 Days) | 110.3K | ★ 3.0M |
| Earning Date | 01-22-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $1,146,429,000.00 | $44,051,000.00 |
| Revenue This Year | $4.11 | N/A |
| Revenue Next Year | $5.94 | $6.41 |
| P/E Ratio | $20.30 | ★ N/A |
| Revenue Growth | ★ 1.62 | N/A |
| 52 Week Low | $17.46 | $0.67 |
| 52 Week High | $30.12 | $3.60 |
| Indicator | CVLG | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 67.12 | 62.17 |
| Support Level | $19.73 | $2.98 |
| Resistance Level | $22.17 | $3.45 |
| Average True Range (ATR) | 0.61 | 0.21 |
| MACD | 0.38 | 0.02 |
| Stochastic Oscillator | 87.77 | 85.55 |
Covenant Logistics Group Inc together with its wholly-owned subsidiaries offers truckload transportation and freight brokerage services to customers throughout the continental United States. The company's reportable segments include Expedited, Dedicated Services, Managed Freight and Warehousing. Expedited segment provides truckload services to customers with high service freight and delivery standards. Dedicated segment provides customers with committed truckload capacity over contracted periods with the goal of three to five years in length. Managed Freight segment includes brokerage services and TMS. Warehousing segment provides day-to-day warehouse management services to customers who have chosen to outsource this function. Majority of revenue is generated from expedited segment.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.